Prosensa Regains Rights to Drisapersen From GSK and Retains Rights to All Other Programs for the Treatment of Duchenne Muscular Dystrophy (DMD)
13 janv. 2014 08h00 HE
|
Prosensa Holding N.V.
LEIDEN, Netherlands and LONDON, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA) and GlaxoSmithKline (GSK) today announced that Prosensa has regained all rights from GSK to...
Prosensa to Present Corporate Overview at the 32nd Annual J.P. Morgan Healthcare Conference
07 janv. 2014 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) announced
today that Hans GCP Schikan, Chief Executive Officer, will present
a corporate overview at the...
Prosensa Comments on Drisapersen Program Update
19 déc. 2013 11h06 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Dec. 19, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
Prosensa Announces Extraordinary Shareholders Meeting to Appoint Dr. Georges Gemayel
10 déc. 2013 09h15 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch
biopharmaceutical company focusing on rare diseases with a high
unmet medical need, today...
Prosensa and Partners Awarded Second European Consortium FP7 Research Grant
25 nov. 2013 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands and Newcastle, UK, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch
biopharmaceutical company focusing on rare diseases with a high
unmet medical...
Prosensa Announces Third Quarter 2013 Financial Results and Recent Corporate Developments
18 nov. 2013 08h00 HE
|
Prosensa Holding N.V.
LEIDEN, The Netherlands, Nov. 18, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high...
Prosensa Awarded Best Biotech Pipeline 2013 at the Rare & Orphan Advocacy and Research (ROAR) Awards
15 nov. 2013 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Nov. 15, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch
biopharmaceutical company focusing on rare diseases with a high
unmet medical need, has been...
Prosensa Holding N.V. to Webcast Conference Call Discussing 3rd Quarter 2013 Financial Results on November 18, 2013
11 nov. 2013 08h09 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Nov. 11, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that the
Company will host a conference call and live audio webcast on
Monday, November...
Prosensa Enrolls 100th Patient to its Natural History Study of Duchenne Muscular Dystrophy
07 nov. 2013 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch
biopharmaceutical company focusing on RNA-modulating therapeutics
for rare diseases with high...
Prosensa to Host Conference Call to Discuss Recent Drisapersen Data Presentations
03 oct. 2013 16h30 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...